364 related articles for article (PubMed ID: 24858818)
61. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
[TBL] [Abstract][Full Text] [Related]
62. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.
Morgado-Palacin I; Day A; Murga M; Lafarga V; Anton ME; Tubbs A; Chen HT; Ergan A; Anderson R; Bhandoola A; Pike KG; Barlaam B; Cadogan E; Wang X; Pierce AJ; Hubbard C; Armstrong SA; Nussenzweig A; Fernandez-Capetillo O
Sci Signal; 2016 Sep; 9(445):ra91. PubMed ID: 27625305
[TBL] [Abstract][Full Text] [Related]
63. Initiation of MLL-rearranged AML is dependent on C/EBPα.
Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
[TBL] [Abstract][Full Text] [Related]
64. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
[TBL] [Abstract][Full Text] [Related]
65. TET1 plays an essential oncogenic role in MLL-rearranged leukemia.
Huang H; Jiang X; Li Z; Li Y; Song CX; He C; Sun M; Chen P; Gurbuxani S; Wang J; Hong GM; Elkahloun AG; Arnovitz S; Wang J; Szulwach K; Lin L; Street C; Wunderlich M; Dawlaty M; Neilly MB; Jaenisch R; Yang FC; Mulloy JC; Jin P; Liu PP; Rowley JD; Xu M; He C; Chen J
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11994-9. PubMed ID: 23818607
[TBL] [Abstract][Full Text] [Related]
66. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
67. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
68. High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome.
Balgobind BV; Zwaan CM; Reinhardt D; Arentsen-Peters TJ; Hollink IH; de Haas V; Kaspers GJ; de Bont ES; Baruchel A; Stary J; Meyer C; Marschalek R; Creutzig U; den Boer ML; Pieters R; van den Heuvel-Eibrink MM
Leukemia; 2010 Dec; 24(12):2048-55. PubMed ID: 20861917
[TBL] [Abstract][Full Text] [Related]
69. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
[TBL] [Abstract][Full Text] [Related]
70. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
Banday S; Farooq Z; Ganai SA; Altaf M
Clin Epigenetics; 2020 May; 12(1):73. PubMed ID: 32450905
[TBL] [Abstract][Full Text] [Related]
71. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
[TBL] [Abstract][Full Text] [Related]
72. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
[TBL] [Abstract][Full Text] [Related]
73. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract][Full Text] [Related]
74. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.
Zhang W; Zhao C; Zhao J; Zhu Y; Weng X; Chen Q; Sun H; Mi JQ; Li J; Zhu J; Chen Z; Pandolfi PP; Chen S; Yan X; Xu J
Theranostics; 2018; 8(16):4359-4371. PubMed ID: 30214626
[TBL] [Abstract][Full Text] [Related]
75. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
76. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
Juszczynski P; Rodig SJ; Ouyang J; O'Donnell E; Takeyama K; Mlynarski W; Mycko K; Szczepanski T; Gaworczyk A; Krivtsov A; Faber J; Sinha AU; Rabinovich GA; Armstrong SA; Kutok JL; Shipp MA
Clin Cancer Res; 2010 Apr; 16(7):2122-30. PubMed ID: 20332322
[TBL] [Abstract][Full Text] [Related]
77. Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.
Liu J; Qin YZ; Yang S; Wang Y; Chang YJ; Zhao T; Jiang Q; Huang XJ
Ann Hematol; 2017 Apr; 96(4):567-574. PubMed ID: 28054140
[TBL] [Abstract][Full Text] [Related]
78. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Stein EM; Garcia-Manero G; Rizzieri DA; Tibes R; Berdeja JG; Savona MR; Jongen-Lavrenic M; Altman JK; Thomson B; Blakemore SJ; Daigle SR; Waters NJ; Suttle AB; Clawson A; Pollock R; Krivtsov A; Armstrong SA; DiMartino J; Hedrick E; Löwenberg B; Tallman MS
Blood; 2018 Jun; 131(24):2661-2669. PubMed ID: 29724899
[TBL] [Abstract][Full Text] [Related]
79. DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
Wood K; Tellier M; Murphy S
Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29495487
[TBL] [Abstract][Full Text] [Related]
80. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
